Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivanisiran - Sylentis

Next Previous
Drug Profile

Tivanisiran - Sylentis

Alternative Names: SYL-1001; SYL-1001 DP

Latest Information Update: 03 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sylentis
  • Class Analgesics; Eye disorder therapies; Gene therapies; Small interfering RNA
  • Mechanism of Action RNA interference; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dry eyes
  • Phase II Ocular pain

Most Recent Events

  • 03 Feb 2026 Tivanisiran is still in phase III trials for Dry eyes in USA
  • 18 Dec 2023 Adverse events data from a phase III trial in Dry eyes released by Sylentis
  • 11 Dec 2023 Sylentis completes a phase-III clinical trials in Dry eyes in USA, Spain (Ophthalmic) (NCT04819269)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top